B. Riley Securities Initiates Coverage On Immunic with Buy Rating, Announces Price Target of $6
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities has initiated coverage on Immunic (NASDAQ:IMUX) with a Buy rating and set a price target of $6, indicating a positive outlook for the company's stock.
August 27, 2024 | 10:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B. Riley Securities has initiated coverage on Immunic with a Buy rating and a price target of $6, suggesting a positive short-term outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target by a reputable analyst can lead to increased investor interest and potential stock price appreciation. The $6 price target suggests a positive outlook, which may attract more buyers.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100